Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
227 hedge funds and large institutions have $4.25B invested in Amicus Therapeutics in 2020 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 74 increasing their positions, 74 reducing their positions, and 17 closing their positions.
924% more call options, than puts
Call options by funds: $43.4M | Put options by funds: $4.23M
153% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 17
60% more capital invested
Capital invested by funds: $2.66B → $4.25B (+$1.59B)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
12% more funds holding
Funds holding: 203 → 227 (+24)
0% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 74
2.41% less ownership
Funds ownership: 111.82% → 109.41% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$26.1M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$25.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.9M |
| 4 |
D.E. Shaw & Co
New York
|
+$18.1M |
| 5 |
JP Morgan Chase
New York
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$54.9M |
| 2 |
Morgan Stanley
New York
|
-$49.1M |
| 3 |
DM
Deerfield Management
New York
|
-$22.4M |
| 4 |
AG
Artal Group
Luxembourg
|
-$18.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.9M |
FOLD Hedge Fund Activity: Q2 2020 in Review
227 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2020, worth a combined $4.25B — up 60% from $2.66B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new FOLD positions and 17 closed out — a net gain of 26 holders — while 74 added to existing stakes and 74 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $26.1M. The largest seller was Victory Capital Management, cutting an estimated $54.9M.
- 227 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2020, up from 203 in Q1 2020.
- Funds reported $4.25B of Amicus Therapeutics stock for Q2 2020, up 60% quarter-over-quarter.
- 43 funds opened new Amicus Therapeutics positions in Q2 2020 and 17 closed out, a net change of +26 holders.
- The largest Amicus Therapeutics buyer in Q2 2020 was Deutsche Bank, an estimated $26.1M added.
- The largest Amicus Therapeutics seller in Q2 2020 was Victory Capital Management, an estimated $54.9M sold.
Based on aggregated 13F filings for Q2 2020.